preclinical evidence from C57BL/6 mice by Huehnchen, P. et al.
OPEN
ORIGINAL ARTICLE
A novel preventive therapy for paclitaxel-induced cognitive
deﬁcits: preclinical evidence from C57BL/6 mice
P Huehnchen1,2,3,8, W Boehmerle1,2,3,8, A Springer4, D Freyer1,5 and M Endres1,2,3,5,6,7
Chemotherapy-induced central nervous system (CNS) neurotoxicity presents an unmet medical need. Patients often report a
cognitive decline in temporal correlation to chemotherapy, particularly for hippocampus-dependent verbal and visuo-spatial
abilities. We treated adult C57Bl/6 mice with 12 × 20 mg kg− 1 paclitaxel (PTX), mimicking clinical conditions of dose-dense
chemotherapy, followed by a pulse of bromodesoxyuridine (BrdU) to label dividing cells. In this model, mice developed
visuo-spatial memory impairments, and we measured peak PTX concentrations in the hippocampus of 230 nM l− 1, which was
sevenfold higher compared with the neocortex. Histologic analysis revealed a reduced hippocampal cell proliferation. In vitro, we
observed severe toxicity in slowly proliferating neural stem cells (NSC) as well as human neuronal progenitor cells after 2 h exposure
to low nanomolar concentrations of PTX. In comparison, mature post-mitotic hippocampal neurons and cell lines of malignant cells
were less vulnerable. In PTX-treated NSC, we observed an increase of intracellular calcium levels, as well as an increased activity of
calpain- and caspase 3/7, suggesting a calcium-dependent mechanism. This cell death pathway could be speciﬁcally inhibited with
lithium, but not glycogen synthase kinase 3 inhibitors, which protected NSC in vitro. In vivo, preemptive treatment of mice with
lithium prevented PTX-induced memory deﬁcits and abnormal adult hippocampal neurogenesis. In summary, we identiﬁed a
molecular pathomechanism, which invokes PTX-induced cytotoxicity in NSC independent of cell cycle status. This pathway could be
pharmacologically inhibited with lithium without impairing paclitaxel’s tubulin-dependent cytostatic mode of action, enabling a
potential translational clinical approach.
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INTRODUCTION
Neurotoxic phenomena are common adverse effects of antineo-
plastic chemotherapy. In the peripheral nervous system, the
development of chemotherapy-induced peripheral neuropathy is
a well-recognized adverse reaction for many substances (reviewed
by ref. 1). Side effects of chemotherapy in the central nervous
system (CNS), in particular, changes in cognitive function (in the
non-medical literature often referred to as ‘chemobrain’ or
‘chemofog’), are more diffuse. A growing body of evidence
underlines the potential of cytostatic drugs to induce cognitive
deﬁcits in humans (reviewed by ref. 2); however, many questions
regarding which substances are capable of inducing this effect as
well as the underlying molecular mechanisms remain unclear.
Patients suffering from post-chemotherapy cognitive impairments
(PCCI) typically report a decline in verbal and visuo-spatial abilities,
executive functions, processing speed and attention span. Meta-
analyses from clinical studies show that patients receiving
chemotherapy performed signiﬁcantly worse in standardized
neuropsychological tests, mainly in the verbal and visuo-spatial
domains.3,4 A number of putative pathomechanisms underlying
PCCI were proposed and include among others (1) mutations in
p-glycoprotein and apolipoprotein E e4, (2) hormonal changes
with reduction of neuroprotective estrogen, (3) DNA damage due
to oxidative stress, (4) chronic ischemia related to anemia and
coagulopathies, (5) dysregulation of the immune system with an
increase of pro-inﬂammatory cytokines and (6) a reduction of
adult hippocampal neurogenesis (reviewed by ref. 5). Considering
the clinical symptoms as well as radiological ﬁndings,6 an impaired
adult hippocampal neurogenesis due to chemotherapy-induced
toxicity presents an intriguing hypothesis.
Another interesting phenomenon is that PCCI also seems to
occur in patients who received chemotherapeutics with poor
blood–brain barrier (BBB) penetration.7,8 Paclitaxel (PTX) is a
microtubule-stabilizing agent that is frequently used to treat a
wide spectrum of solid tumors such as breast, ovarian and non-
small cell lung cancer (reviewed by ref. 9). It is a highly lipophilic
substance that easily crosses the BBB, however it is quickly
eliminated from the CNS by an active (p-glycoprotein-mediated)
transporter mechanism.10 Despite poor BBB penetration PTX-
induced transient encephalopathy is well documented.11–13
Although PCCI was reported in patients with PTX combination
therapy (for example, ref. 14), the question whether PTX treatment
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can induce memory deﬁcits in rodents remains controversial with
some studies reporting an effect of taxanes (PTX or docetaxel) on
rodent cognition,15–17 while others do not.18
In the present study, we aimed to characterize the effects of
dose-dense PTX therapy, a clinical treatment regimen that uses
smaller dosages in more frequent applications,19 on spatial
learning and memory in C57Bl/6 mice. More importantly, we
aimed to further elucidate the cellular and molecular mechanisms
of cytotoxicity and to establish a preventive strategy.
MATERIALS AND METHODS
Experimental procedures are described in more detail in the
Supplementary Information.
In vitro
Cell culture. All experimental procedures conformed to institutional
guidelines and were approved by an ofﬁcial committee (Landesamt für
Gesundheit und Soziales, Berlin, Germany). Microdissection, preparation
and maintenance of mouse neural stem cells (NSC) on 2- to 4-week-old
C57Bl/6 mice were conducted as described previously.20 The ability of cells
to generate neurons and glia were routinely checked. For cytotoxicity and
caspase assays, cells were plated on 96-well ﬂat bottom plates (BD
Biosciences, Billerica, MA, USA) and PTX toxicity was induced 24 h after
passage of cells. Preparation and culture of hippocampal neurons (HCN)
was conducted on C57Bl/6 embryos E14 as published previously.21 Human
neuronal progenitor cells were derived from human pluripotent stem cells
by dual SMAD inhibition as described before.22 Cell differentiation was
conﬁrmed by staining for Nestin, SOX 1 and 2 as well as PAX-6 (A24354,
ThermoFisher, Darmstadt, Germany) prior to toxicity analysis. For
cytotoxicity and caspase assays, cells were plated on 96-well ﬂat bottom
plates (BD Biosciences) and cytotoxicity experiments were conducted with
the same protocol as for NSC. MCF-7 and HeLa cell lines were obtained
from Sigma-Aldrich (Taufkirchen, Germany; Authentication by STR proﬁl-
ing). Cell culture was performed as described before.23
Live cell imaging. Imaging of NSC cultured on 8 well Ibidi μ-Slides (Ibidi,
Martinsried, Germany) and loaded with 5 μM Fura-2/AM was performed as
described previously.24 Resting Ca2+ concentrations were measured after
incubation for 2 h with 30 nM PTX or vehicle (VEH).
Cell viability and caspase activity assays. Cell viability was calculated as a
compound measure of cytotoxicity and metabolic integrity and caspase
activity was measured with commercial assays as described previously.24
Fluorescent-activated cell sorting. DNA content was determined by
staining with propidium iodide (Abcam, Cambridge, UK) after exposure
of NSC with PTX or VEH. Cells were measured immediately on a FACS
Canto II (BD Biosciences, Heidelberg, Germany). Data were obtained from
three individual experiments and analyzed using FlowJo software
(Ashland, OR, USA).
Western blot analysis. Lysate preparation and immunoblotting was
performed with as reported previously.25
In vivo
Animal numbers, housing conditions and study approval. A total of 127
nine-week old male C57BL/6 N mice from Charles River (Sulzfeld, Germany)
were used for this study. All experimental procedures conformed to animal
welfare guidelines and were previously approved by an ofﬁcial committee
(Landesamt für Gesundheit und Soziales, Berlin, Germany). Mice were
housed in groups of ﬁve in an enriched environment and allowed food and
water ad libitum. The animals were maintained on a 12:12 h light/dark
cycle (0700 hours–1900 hours) and behavioral testing was conducted
between 1000 hours and 1600 hours. Injections coinciding with behavior
tests were administered after all testing had been completed. The general
wellbeing of the mice was assessed daily and their weight recorded on a
regular basis.
Sample sizes and methods of randomization and blinding. We chose a
mouse model of dose-dense PTX therapy to evaluate changes of cognition
induced by PTX treatment.26 Overall four different sets of animal
experiments were performed: (1) In the initial trial, we used 15 animals
for the treatment and 10 animals for the control group, as previous studies
reported a mortality of 25–50% for repeated 20 mg kg− 1 body weight
(BW) PTX injections in mice.27 (2) In the second experiment, we studied
possible traits of anxiety and depression. We determined the group size
based on the observations of the ﬁrst experiment, with a desired power of
0.8 and an alpha level of 0.05 using SigmaPlot software (Systat, Richmond,
CA, USA). Having expected a smaller effect size, we calculated n=15
animals per group. (3) An additional 12 PTX and lithium carbonate (Li+)-
injected animals were used to measure pharmacokinetics (2 mice per time
point as described below). (4) In the last step, a preventive application of
Li+ in PTX and VEH-treated mice was assessed. The calculated sample size
with four different groups (VEH/VEH; PTX/VEH; VEH/Li+; PTX/Li+) was n=15
animals per group.
Upon arrival of the animals in the animal facility, unequal block
randomization was performed28 to determine group and cage allocation.
All injections of substances (PTX; VEH; Li+) were carried out by one
examiner. The investigators conducting the behavior experiments as well
as histological analysis were blinded throughout the entire process
including statistical analysis.
Drug injection protocol. PTX (Sigma-Aldrich) was dissolved in Cremophor
EL: Ethanol (1:1) to a concentration of 6 mg ml− 1 and diluted in sterile
0.9% NaCl solution to a ﬁnal concentration of 2 mg ml− 1 before
intraperitoneal (i.p.) injection of 20 mg kg− 1 BW PTX. Animals in the
control group received an equal volume of vehicle (Cremophor EL: Ethanol,
1:1, diluted in sterile 0.9% NaCl solution to a ﬁnal concentration of 33.3%
Cremophor EL: Ethanol) via i.p. injection.
For the interventional trial, lithium carbonate (Li+) was dissolved in
sterile 0.9% NaCl solution to a ﬁnal concentration of 1.28 mg ml− 1 before i.
p. injection and 170 μM Li+/kg BW were injected before administration of
PTX or VEH.
5-Bromo-2′-deoxyuridine (BrdU; Sigma-Aldrich) was dissolved in 0.9%
sterile NaCl and injected at a concentration of 50 mg kg− 1 i.p. 24 h after
the last PTX injection to label dividing cells in all experiments.
Pharmacokinetic analysis. After injection of 20 mg kg− 1 PTX, respectively,
170 μM Li+, two animals each were maintained for 15, 30, 60, 120, 240 and
720 min before ﬁnal anesthesia. Blood was drawn from the V. cava inferior
before exsanguination with 0.9% NaCl. Brains were rapidly extracted,
dissected and snap frozen in liquid nitrogen. Blood samples were
centrifuged and remaining serum was snap frozen in liquid nitrogen.
Samples were prepared for analysis with liquid chromatography-tandem
mass spectrometry with an adapted previously described protocol.29
Analysis was performed by UPLC-MS/MS with an Acquity UPLC—Synapt
G2-S HDMS system equipped with an Acquity UPLC C18 1.7 μm
2.1 × 50 mm column (all by Waters, Eschborn, Germany). For MS/MS
experiments, the [M+H]+ ion with m/z 854.2 was isolated and submitted to
fragmentation, resulting in an intensive fragment ion with m/z 509.304,
which was used for quantiﬁcation (Supplementary Figure S1). Lithium
serum concentrations were measured with a commercial polyﬂuoropor-
phyrin assay (Funakoshi, Tokyo, Japan) according to manufacturer’s
instructions.
Behavior analysis. To familiarize animals to the investigator, handling of
animals was carried out for ﬁve consecutive days prior to start of the
experiment. During behavioral testing, cages and animals were randomly
selected for testing by a blinded experimenter. All behavior tests were
carried out in a dedicated laboratory with soundproof chambers. The
Morris water maze task, open ﬁeld test, elevated plus maze, Porsolt forced-
swim test, novelty-induced suppression of feeding and sucrose consump-
tion test were conducted as described previously.30–32
Histology. After exsanguination with NaCl animals were transcardially
perfused with 4% paraformaldehyde (PFA) solution for 15 min. Subsequent
to decapitation, brains were extracted and immediately ﬁxed in 4% PFA at
4 °C. Afterwards brains were washed and kept overnight in 20% sucrose.
After dehydration, brains were placed in cryomatrix and frozen in methyl
butane at − 50 to − 60 °C.
Immunohistochemistry. Slides were rehydrated through a series of graded
ethanol baths and rinsed with phosphate buffered saline (PBS, pH 7.4)
prior to 30 min of antigen retrieval at 100 °C in 10 mM sodium citrate buffer
pH 6. Unspeciﬁc binding sites were blocked with 10% normal goat serum
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(NGS) in PBS with 0.1% Triton-X-100 (Sigma-Aldrich) then incubated
overnight with rat anti-BrdU antibody (1:500; AbD Serotec, Kidlington, UK)
diluted in 10% NGS at 4 °C. In each experiment, a negative control
without primary antibody was included. After washing and blocking,
secondary biotinylated anti-rat antibody was applied for 2 h (1:250; Life
Technologies, Carlsbad, CA, USA) diluted in 10% NGS at room temperature.
ABC reagent (Vectastain Elite, Vector Laboratories, Burlingame, CA, USA)
was applied for 1 h at a concentration of 9 μl ml− 1 followed by
diaminobenzidine staining (DAB, Sigma-Aldrich) in the presence of
0.01% H2O2. One-in-10 series of sections (200 μm apart) from all animals
were stained and analyzed.
Immunoﬂuorescence. Slides were treated as mentioned above using the
following primary antibodies and dilutions: mouse anti-NeuN biotin
conjugated 1:100 (MAB377B, Millipore, Schwalbach, Germany), rabbit
anti-Doublecortin 1:250 (ab18723, abcam, Cambridge, UK), rat anti-BrdU
1:500 (OBT0030, AbD Serotec). After washing and blocking, primary
antibodies were detected with a ﬂuorophore coupled secondary antibody:
Alexa 488-conjugated streptavidin for Biotin-conjugated primaries, goat
anti-rabbit IgG Alexa 488, goat anti-mouse IgG Alexa 488, goat anti-rat IgG
Alexa 546, goat anti-mouse IgG Alexa 633, goat anti-rabbit IgG Alexa 633
(all 1:250, Life Technologies). Slides were mounted with ProLong Gold
antifade reagent with DAPI (Life Technologies).
Cell counts: Cell counts were determined in one-in-10 series of sections
covering the entire hippocampus in its rostrocaudal extension. Cell
counting was performed by a blinded investigator. Appropriate gain and
black level settings were determined on control slices stained with
secondary antibodies alone.
Stereology: Postmitotic neurons were NeuN-DAB stained in coronal
sections (one-in-10 series, 200 μm apart) of 28 randomly chosen animals
(n=7 per group of the PTX/Li+ trial). The absolute cell number was
determined by a blinded investigator using a semiautomatic stereology
system (Stereo Investigator, MicroBrightField Bioscience, Williston, VT,
USA), linked to a Leica DMRE microscope (Leica, Nussloch, Germany).
Data processing, exclusion criteria and statistical analysis. The manuscript
was written in accordance with ARRIVE guidelines.33 Data are presented as
mean± s.e.m. with individual data points or box-whisker-plot (minimum to
maximum). All data processing and analysis were completed before
unblinding of the analyzer. Data were checked for Gaussian distribution
prior to statistical analysis using D’Agostino–Pearson normality test.
Statistical analysis was performed using Prism v7.0 (GraphPad Software,
La Jolla, CA, USA). Normally distributed data were analyzed using unpaired
two-sided t-tests (two groups) or ordinary one-way ANOVA with Holm–
Sidak post hoc analysis for multiple comparisons (⩾3 groups). Analysis of
two variables was done by (repeated-measures) two-way ANOVA and post
hoc analysis of multiple comparisons by controlling the false discovery rate
(Benjamini and Hochberg method). Not normally distributed data were
analyzed with Mann–Whitney U test (two groups). Po0.05 was considered
statistically signiﬁcant and is depicted by an asterisk (NS: not signiﬁcant).
Only statistical outliers that met Peirce’s criterion were excluded from the
data set.34,35 Sample size calculation was done prior to execution of in vivo
experiments based on published effect sizes and expected standard
deviations. In vitro data including ﬂuorescent-activated cell sorting analysis
was obtained from n= 3 biological replicates unless stated otherwise.
RESULTS
We used a mouse model of dose-dense PTX therapy where male
adult C57Bl/6 mice receive 12 i.p. injections of 20 mg kg− 1 BW PTX
on alternating weekdays over the course of 4 weeks (human
equivalent dose of 12 × 65 mg m− 2). The injection protocol
(Figure 1a) mimics dose and application frequency of weekly
PTX infusions in patients, a paradigm established for instance in
breast cancer treatment. We have previously shown that this
schedule leads to an axonal-sensory neuropathy but is otherwise
well tolerated.26
PTX concentrations in different brain regions
PTX is known to reach only low concentrations in the CNS due
to active excretion by p-glycoprotein.36,37 Given that both
visuo-spatial and verbal memory abilities largely depend on
hippocampal integrity, we were interested if PTX concentrations
would differ between various brain regions. We measured PTX
concentrations in serum and brain homogenate samples obtained
from two animals per time point from 15 min to 12 h after a single
i.p. injection of PTX using ultra high-pressure liquid chromato-
graphy and tandem mass spectrometry. In line with previous
reports,37 PTX serum concentrations were ~ 70-fold higher than
PTX levels in the brain. Interestingly, PTX concentrations were
increased sevenfold in the hippocampus compared with the levels
in the neocortex and reached peak concentrations close to
230 nM l−1 (Figure 1b).
PTX therapy impairs spatial memory
To test for a possible visuo-spatial impairment, we used the Morris
water maze task (MWM), which is based on the paradigm that
rodents are able to learn the location of a hidden platform in a
swimming pool by memorizing its spatial relation to visual cues.38
Potentially confounding unspeciﬁc toxic effects from PTX treat-
ment were minimized by an 8-days-long recovery period between
the last PTX injection and the MWM, which consisted of a 7 days
training period (place task) followed by a single probe trial on day
8. PTX-treated animals were slower to learn the location of the
hidden platform during training (Supplementary Figure S2A),
whereas parameters of motor performance were comparable
between PTX and VEH groups. In the concluding spatial probe
trial, the platform was removed and the swim patterns of VEH-
and PTX-treated mice were recorded (Figure 1c). Animals with
previous PTX therapy spent signiﬁcantly less time and covered less
distance in the quadrant that previously contained the platform
(P= 0.039 (time), respectively, 0.018 (distance); group sizes: n= 10
(VEH); n= 15 (PTX); unpaired two-sided t-test; Figures 1d and e).
Importantly, total distance traveled and swim speed were
comparable between groups, indicating that PTX-induced neuro-
pathy did not have an impact on water maze performance
(Figures 1f and g). As the MWM has a high sensitivity for detecting
hippocampus-based spatial cognitive function in rodents,39 these
results suggest that systemic dose-dense PTX therapy might affect
hippocampal structures leading to the observed phenotype.
PTX treatment has no effects on affective behavior
Chemotherapy is one potential cofactor for the development of
neuropsychiatric sequelae such as anxiety and depression, which
is observed in many cancer patients (reviewed by ref. 40). As
behavioral changes associated with affective disorders could
confound our observations regarding spatial learning, memory
and neurogenesis, we conducted a second PTX trial and tested
mice for behavioral signs of anxiety, depression or despair. No
differences were observed between PTX and VEH-treated mice in
monitored movements through a novel open ﬁeld (Figures 2a and
b) or an elevated plus maze (Figure 2c), tests which would indicate
increased anxiety. In contrast to typical ﬁndings related to anxiety
in a conﬂicting forced-choice situation, we recorded a small but
signiﬁcant decrease in the feeding latency of the PTX group in the
novelty-induced suppression of feeding test (P= 0.048; group
sizes: n= 15 (VEH) and n= 13 (PTX); unpaired two-sided t-tests;
Figure 2d). Furthermore, PTX-treated mice neither showed signs of
despair in their response to a desperate situation (Porsolt forced-
swimming test; Figure 2e) nor anhedonic behavior (sucrose consump-
tion test; Figure 2f). In summary, we did not detect any relevant
alterations of affective behavior in mice after PTX treatment.
PTX induces cytotoxicity in NSC through a calpain- and
caspase-mediated mechanism
It was previously shown that a reduction of hippocampal adult
neurogenesis leads to impaired spatial learning and memory.41,42
Considering our behavioral observations and that PTX levels were
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higher in the hippocampus than in the neocortex, we hypothe-
sized that cognitive deﬁcits after PTX therapy could be attributed
to an impaired hippocampal neurogenesis. We therefore exam-
ined effects of PTX on cultured mouse NSC in vitro. In our
pharmacokinetics proﬁle, PTX concentrations peaked at 2 h
(serum) and 4 h (brain) post injection, respectively. We therefore
chose a more conservative timeframe of 2 h PTX exposure for our
experiments. When we exposed NSC with various PTX concentra-
tions ranging from 3 pM to 3 μM for 2 h, we observed severe
cytotoxicity even in the low nanomolar concentration range,
despite the short exposure time (Supplementary Figure S3a). The
calculated EC50 for NSC in the dose–response curve was 27 nM
(non-linear regression ﬁt; Figure 3a). Human neuronal progenitor
cells (hNPC) derived from induced pluripotent stem cells (iPSC)
were equally sensitive with a calculated EC50 of 4 nM (non-linear
regression ﬁt; Figure 3a). In contrast to NSC and hNPC, mouse
mature HCN were less susceptible to the same treatment with a
calculated EC50 of 4700 nM (non-linear regression ﬁt; Figure 3a). As
the division rate of adult NSC is low compared to malignant cells,
we considered it unlikely that the observed severe cytotoxicity in
NSC could solely be attributed to PTX’ cytostatic properties, which
are only exerted during the M-phase of the cell cycle. In our NSC
cultures, we observed an average cycle time of 2.3 days, which is
in line with previously published data.43 In a next step, we
measured the percentage of NSC in the G2/M-phase. After 2 h
exposure to VEH or PTX, only 6.1% of VEH- and 7.6% of PTX-
treated cells were in the G2/M-phase (not signiﬁcant; Figure 3b),
whereas the largest portion of cells were in the G1-phase. On the
basis of the previously established dose–response curve, we chose
a 30 nМ PTX dose for subsequent experiments, which reduced cell
viability to 48 ± 5% compared with VEH-treated controls. The
ratiometric calcium (Ca2+) indicator Fura-2 was used to assess
cytoplasmic baseline Ca2+ levels after PTX treatment. In PTX-
treated cells compared with VEH exposed controls, we observed a
signiﬁcantly higher λ340/380 nm excitation ratio (Po0.0001;
n= 53 (PTX), n= 68 (VEH) cells, ﬁve replicates; two-sided t-test;
Figure 3c). We next investigated apoptotic cell death as a possible
mechanism. When we measured activity of the executioner
caspases 3/7 at different time points, we observed a marked
increase of activity 12 h post PTX treatment (P⩽ 0.0001; F(3, 24)
=14.32; ordinary one-way ANOVA; Figure 3d). Notably, the
calculated EC50 for caspase 3/7 activation was 16 nm (non-linear
regression ﬁt, Figure 3e). We next tested caspases upstream of
caspase 3/7 and also observed an increase of caspase 9 activity
(Figure 3e).
In regards to the observed increase of baseline Ca2+ levels after
PTX treatment, we have previously demonstrated, that PTX can
bind to the protein neuronal calcium sensor-1 (NCS-1), increasing
positive modulation of the inositol 1,4,5-trisphosphate receptor
(InsP3R1) and causing elevated levels of intracellular Ca
2+ .44 In
dorsal root ganglia sensory neurons (DRGN), this increase of Ca2+
is sufﬁcient to activate the Ca2+-dependent protease calpain25
and thereby contributes to the development of a PTX-induced
peripheral neuropathy. We hypothesized, that the same
Figure 1. Effects of dose-dense paclitaxel (PTX) treatment on spatial memory. (a) Schedule of dose-dense PTX treatment and the Morris water
maze (MWM) experiment. Animals received a total of 12 intraperitoneal (i.p.) PTX injections with 20 mg kg− 1 BW each (three times per week
over the course of 4 weeks). Animals were allowed to rest for 8 days prior to training in the MWM. (b) PTX serum and tissue concentrations at
15, 30, 60, 120, 240 and 720 min after single i.p. PTX injection with 20 mg kg− 1 body weight (BW): serum levels (left y axis) were almost two
orders of magnitude higher compared with the brain concentrations (right y axis). In the brain, PTX levels measured in the hippocampus were
approximately sevenfold higher than those measured in the neocortex. (c) In the MWM, PTX-treated mice performed worse in the probe trial:
representative images of swim patterns from a VEH- and PTX-treated mouse. (d) Compared to controls, PTX-treated mice spent signiﬁcantly
less time and (e) swam signiﬁcantly shorter distances in the target quadrant, whereas (f) the overall distances covered and (g) swim speed
were comparable. Statistical analysis: (b) No statistical analysis was performed (n= 2 per time point). (d–g) Data were checked for normal
distribution using D’Agostino–Pearson normality test and thereafter analyzed using unpaired two-sided t-tests (group sizes: n= 10 (VEH);
n= 15 (PTX)). *Po0.05; NS, not signiﬁcant.
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mechanism might initiate caspase activation and cell death in NSC
and that cell-speciﬁc expression of NCS-1, respectively, InsP3R1
may lead to differential effects on various cell types. When we
tested protein expression levels of NCS-1, we observed a strong
expression in cultured NSC but not HCN or in a human breast
cancer cell line (MCF-7). NSC additionally showed stronger protein
expression levels of the InsP3R1 compared with HCN (Figure 3f).
Measurements of calpain activity in NSC revealed a signiﬁcant
increase as early as 1 h after PTX exposure, which could be
inhibited with the calpain inhibitor MDL28170 (Po0.0001; F(3,
26) = 29.68; ordinary one-way ANOVA; Figure 3g and
Supplementary Figure S3F). We previously established that the
interaction of NCS-1 with the InsP3R1 can be speciﬁcally inhibited
with lithium ions (Li+).45 Further assessment of caspase 3/7 activity
showed that the PTX-induced increase of caspase 3/7 activity was
inhibited by co-treatment with a caspase 3/7 inhibitor (AC-DEVD-
CHO), with the calpain inhibitor MDL28170 and Li+ (Po0.0001;
F(5, 48) = 52.02; ordinary one-way ANOVA; Figure 3d and
Supplementary Figure S3G). However, A1070722, a selective
inhibitor of glycogen synthase kinase 3 beta (GSK3β), which is a
known molecular target of Li+, had no effect (Figure 3d). We next
tested whether interference with intracellular Ca2+ signaling
would affect cell viability after PTX exposure. Inhibition of calpain,
but more effectively co-treatment with Li+, restored decreased
cell viability of PTX exposed NSC to almost control levels
(Po0.0001; F(5, 30) = 112.7; ordinary one-way ANOVA; Figure 3h
and Supplementary Figures S3B, S3D and S3E), whereas inhibition
of GSK3 had no inﬂuence. Albeit not signiﬁcant, cell viability of
PTX/Li+-treated NSC was still slightly reduced by 16% compared
with VEH treatment, which might be explained by PTX’ cytostatic
mechanism of action towards NSC. In comparison to the
observations in NSC, malignant cells from the human breast
cancer cell line MCF-7 and cervical cancer cell line HeLa, were less
sensitive to PTX and were not protected by lithium co-medication
(Figure 3i). Taken together, our results suggest that observed PTX
concentrations in the hippocampus after systemic application are
sufﬁcient to induce cell death in NSC independent of cell cycle
status. Owing to the short exposure time and the vulnerability of
NSC, cytotoxicity in this condition appears to be mediated mainly
by Ca2+ and caspase-dependent mechanisms and only to a much
lesser extent by PTX’ effects on the microtubule cytoskeleton.
Lithium co-treatment prevents PTX-induced cognitive changes
To test the hypothesis that co-treatment with Li+ prevents PTX-
mediated toxicity towards NSC and progenitor cells, and that NSC
toxicity could be relevant for the development of visual-spatial
deﬁcits, we studied the efﬁcacy of preventive Li+ application in
PTX therapy. Animals were randomly assigned to four groups and
injected either with 12.8 mg kg− 1 BW Li+ or sodium chloride (VEH)
Figure 2. Paclitaxel (PTX) has no effect on anxiety and depression related behavior. (a) Dose-dense PTX treatment affected neither the total
distance traveled nor (b) the time spent in the center of a novel open ﬁeld. (c) PTX and vehicle (VEH)-treated animals spent a comparable
amount of time in the open arms of an elevated plus maze. (d) Animals treated with PTX showed a small but signiﬁcant decrease in the
latency to start eating in a novel environment, whereas (e) latency to start ﬂoating in the Porsolt forced-swim test and (f) sucrose consumption
per body weight was comparable between groups. Statistical analysis: data were checked for normal distribution using D’Agostino–Pearson
normality test and thereafter analyzed using (a–e) unpaired two-sided t-tests (group sizes: n= 15 (VEH) and n= 13 (PTX)) and (f) repeated-
measures two-way ANOVA and Benjamini and Hochberg post hoc test (group sizes each: n= 27). *Po0.05; NS not signiﬁcant.
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Figure 3. Paclitaxel (PTX)-induced cytotoxicity in neural stem cells (NSC). (a) Dose–response curve of cytotoxicity in mouse NSC (black dots),
induced pluripotent stem cells (iPSC)-derived human neuronal progenitor cells (hNPC, open triangle) and post-mitotic mouse hippocampus
neurons (HCN; clear dots) after 2 h exposure time with PTX. Data were ﬁtted with a three-parameter logistic curve. (b) Representative
histogram of cell cycle analysis in NSC. After both vehicle (VEH), respectively, PTX treatment, only small percentages of NSC were in G2/M-
phase (insert). (c) Treatment of NSC with 30 nM PTX led to a signiﬁcant increase in resting Ca2+ levels, evidenced by a higher Fura-2 excitation
ratio. (d) Caspase-3/7 activity was signiﬁcantly increased after PTX treatment (30 nM) and was inhibited by co-incubation with the calpain
inhibitor MDL28170 (Calp-Inh; 10 μM), lithium chloride (Li+; 1 mM), and the caspase inhibitor AC-DEVD-CHO (C3/7-Inh; 1 μM). Caspase-3/7
activity remained high after co-treatment with the GSK3β inhibitor A1070722 (GSK3-Inh; 100 nM). (e) Dose–response curve of caspase 3/7
(closed circles) and caspase 9 (open squares) activity in NSC 12 h after 2 h exposure with different PTX concentrations. (f) Protein expression of
NCS-1 is higher in NSC compared with HCN and MCF-7 breast cancer cells. (Loading control of whole cell lysates: HDAC-1). (g) PTX induces an
increase in calpain activity which could be prevented with the calpain inhibitor MDL28170 (Calp-Inh; 10 μM). (h) Impaired cell viability of NSC
after exposure to 30 nM PTX was signiﬁcantly improved by co-incubation with MDL28170 (Calp-Inh; 10 μM), Li+ (1 mM) or AC-DEVD-CHO (C3/7-
Inh; 1 μM), respectively, but not with the GSK3β inhibitor A1070722. (i) Exposure of MCF-7 and HeLa cells to different PTX concentrations for
2 h with and without 1 mM Li+ did not show a protective effect for the lithium co-medication in these cancer cell lines. Statistical analysis: data
were checked for normal distribution using D’Agostino–Pearson normality test and then analyzed using (b) Mann–Whitney U test, (c) unpaired
two-sided t-test and (d-e and g–i) ordinary one-way ANOVA and Holm–Sidak post hoc test (data are obtained from n= 3 individual
experiments with 4–6 technical replicates for each condition). *Po0.05; NS, not signiﬁcant.
Prevention of paclitaxel-induced neurotoxicity
P Huehnchen et al
6
Translational Psychiatry (2017), 1 – 11
15 min prior to every application of PTX or VEH. This previously
established dose46 yielded non-toxic serum levels in the high
micromolar dose range (Figure 4a). The treatment was generally
well tolerated with normal spontaneous behavior observed in all
treatment groups, however 4 out of 60 animals died due to
injection related complications (2 VEH/Li+; 1 PTX/VEH; 1 PTX/Li+).
Mice in the PTX/VEH, and to a lesser extent in the PTX/Li+ group,
showed a moderate weight loss during therapy, which rapidly
recovered after the last injection (Figure 4b). Similar to our
pilot trial, we observed longer latencies for mice of the PTX/VEH
group to locate the hidden platform during MWM training
(Supplementary Figure S2B). The same pattern was maintained
in the probe trial: PTX/VEH injected mice took longer to locate the
former position of the platform (data not shown), spent
signiﬁcantly less time in the target quadrant (P= 0.03; F(1,
43) = 4956; ordinary two-way ANOVA and Benjamini and Hochberg
Figure 4. Effects of Li+ on paclitaxel (PTX)-induced cognitive deﬁcits. In a ﬁrst step, the pharmacokinetics of Li+ was assessed: (a) Li+ serum
concentrations were measured after a single intraperitoneal (i.p.) injection with 12.8 mg kg− 1 BW lithium carbonate. The observed decay is
consistent with a two-compartment model. Next, four groups of animals were treated with PTX or vehicle (VEH) and Li+ or the respective VEH.
(b) PTX/VEH-treated animals (gray dotted line) had a moderate but signiﬁcant weight loss compared with VEH/VEH-treated animals (black
solid line), which was less pronounced in the PTX/Li+ group (gray dashed line). Duration of PTX treatment is marked by bar above the graph.
(c) Representative swim patterns of VEH/VEH, VEH/Li+, PTX/VEH and PTX/Li+-treated mice recorded in the probe trial of the MWM task, in
which (d) PTX/VEH-treated animals spent signiﬁcantly less time and covered (e) less distance in the target quadrant compared with the PTX/
Li+ and VEH groups whereas (f) overall distance covered and (g) swim speed was similar between the groups. Statistical analysis: data were
checked for normal distribution using the D’Agostino–Pearson normality test and then analyzed using (d–g) ordinary two-way ANOVA and
Benjamini and Hochberg post hoc test (group sizes: n= 11 (VEH/VEH): n= 13 (PTX/Li+); n= 11 (PTX/VEH); n= 12 (VEH/Li+)). *Po0.05; NS, not
signiﬁcant.
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post hoc test; group sizes: n= 11 (VEH/VEH), n= 13 (PTX/Li+); n= 11
(PTX/VEH); n= 12 (VEH/Li+); Figures 4c and d) and covered a
shorter distance in the target quadrant (P= 0.02; F(1, 43) = 6072;
ordinary two-way ANOVA and Benjamini and Hochberg post hoc
test; group sizes: n= 11 (VEH/VEH), n= 13 (PTX/Li+); n= 11 (PTX/
VEH); n= 12 (VEH/Li+); Figure 4e). Animals which received PTX and
the preventive intervention with Li+ performed equally well
compared with the control groups (Figures 4c–e), and all animals
covered comparable total distances and showed similar swim
speeds (Figures 4f and g). Taken together, our results suggest that
preemptive co-treatment with Li+ prevents PTX-induced changes
of visual-spatial function in rodents.
PTX treatment alters adult neurogenesis of the dentate gyrus
In a next step we were interested, if increased cell death of
resident NSC affects hippocampal cell proliferation and neuronal
differentiation in vivo. Therefore, we injected a pulse of BrdU, a
nucleoside analog that is taken up into the DNA of replicating cells
during S-phase,47 24 h after the last PTX treatment in the Li+
intervention trial. Analysis revealed fewer BrdU-positive cells in the
dentate gyrus (DG) of the PTX/VEH group (P= 0.0083; F(1,
45) = 7616; ordinary two-way ANOVA and Benjamini and Hochberg
post hoc test; group sizes: n= 14 (VEH/VEH); n= 10 (VEH/Li+), n= 13
(PTX/Li+); n= 12 (PTX/VEH); Figures 5a and b), whereas PTX/Li+ and
VEH/VEH-treated mice showed comparable numbers. When we
tracked these stem and progenitor cells by colocalization with
other markers, we observed a decrease of immature neuronal cells
(BrdU/doublecortin positive cells (BrdU+/Dcx+); P= 0.0001; F(1,
45) = 128; ordinary two-way ANOVA and Benjamini and Hochberg
post hoc test; group sizes: n= 14 (VEH/VEH); n= 10 (VEH/Li+), n=
13 (PTX/Li+); n= 12 (PTX/VEH); Figure 5c) in the PTX/VEH group
only. We also detected fewer newly generated mature neurons
(BrdU/NeuN-positive cells; P= 0.0076; F(1, 45) = 7818; ordinary two-
way ANOVA and Benjamini and Hochberg post hoc test; group
sizes: n= 14 (VEH/VEH); n= 10 (VEH/Li+), n= 13 (PTX/Li+); n= 12
(PTX/VEH); Figure 5d) after PTX but not Li+ treatment, whereas the
number of BrdU/Iba-1 double positive microglia was comparable
between the four groups (Figure 5e). Interestingly, we observed a
positive statistical correlation between the number of BrdU-
positive neurons and water maze performance in the probe trial
after PTX/VEH treatment (Pearson correlation coefﬁcient (pcc) =
0.67; n= 10 animals; Figure 5f). In the other treatment groups, this
kind of correlation did not reach statistical signiﬁcance. As PTX-
induced cell death of pre-existing post-mitotic neurons in the
hippocampal formation could also account for our behavioral
phenotype, we performed stereological cell counting of post-
mitotic mature neurons (NeuN) in the DG and Cornu ammonis 3
(CA3) region. Our obtained calculations for total cell count and
Figure 5. Neurogenesis in the dentate gyrus of the hippocampus is affected by paclitaxel (PTX) therapy. (a) Representative image of 5-Bromo-
2′-deoxyuridine (BrdU)-positive cells in the dentate gyrus (DG) co-expressing the mature neuronal marker NeuN; scale bar is 10 μm. Insert
shows enlarged image of BrdU/NeuN-positive cell (scale bar is 5 μm). (b) PTX/VEH-treated animals had signiﬁcantly fewer BrdU-positive cells
compared with VEH/VEH and PTX/Li+ treatment groups and (c) the number of newly generated immature neurons (BrdU+/Dcx+) was
signiﬁcantly reduced in the PTX/VEH group only, whereas Li+ application prevented these changes. (d) Further phenotyping of BrdU-positive
cells revealed that in the PTX/VEH group signiﬁcantly fewer cells were positive for NeuN. (e) Cell counts for BrdU-positive microglia cells (BrdU
+/Iba-1+) were comparable across all groups. (f) The number of BrdU/NeuN-positive cells in the PTX/VEH group correlated positively with
water maze performance during the probe trial. (g) Stereological counting showed similar total numbers of NeuN+ cells in the DG region. (h)
Analysis of the dentate gyrus volume showed no evidence of hippocampal shrinkage in PTX-treated groups. Statistical analysis: data were
checked for normal distribution using D’Agostino–Pearson normality test and then analyzed using ordinary two-way ANOVA and Benjamini
and Hochberg post hoc test (group sizes: (b–e): n= 14 (VEH/VEH); n= 13 (PTX/Li+); n= 12 (PTX/VEH); n= 10 (VEH/Li+); (g, h) group sizes n= 7 (all
groups)). (f) Pearson correlation coefﬁcient and 95% conﬁdence band was calculated between BrdU/NeuN-positive cells and Morris water
maze performance for n= 10 animals of the PTX/VEH group. *Po0.05; NS, not signiﬁcant.
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volume were comparable with previous literature.48 In this
analysis, we did not detect any differences in the total number
of neurons in the DG (Figure 5g) and CA3 region (data not shown)
between the four groups, nor a difference in DG volume
(Figure 5h). The lack of difference in absolute NeuN-positive cells,
despite of a reduced neurogenesis after PTX therapy, is most likely
due to a lack of sensitivity of this method with a comparatively
high inherent variance. Nonetheless, this ﬁnding underlines our
observations in cultured cells, which suggest that HCN are much
less sensitive to PTX than NSC.
In summary, these ﬁndings agree with our in vitro data, which
point to an increased vulnerability of neural stem and progenitor
cells to PTX. Moreover, we were able to show that preemptive Li+
treatment prevents PTX-induced behavioral and histological
changes.
DISCUSSION
Up to 50% of patients undergoing systemic chemotherapy report
cognitive impairment in temporal correlation to therapy.49 In spite
of the high incidence of cognitive dysfunction reported after
chemotherapy, the performance in neuropsychological tests
frequently correlates poorly with patients’ subjective perception
resulting in a great heterogeneity of the clinical data (reviewed by
refs 50–53). However, preclinical ﬁndings (reviewed by ref. 54) and
the structural changes observed in imaging studies55 suggest a
neurobiological basis for PCCI. This interpretation is supported by
a growing number of preclinical studies, which report cognitive
changes for instance in mice treated with 5-ﬂuoruracil and
oxaliplatin56 and rats following treatment with a taxane (for
example, refs 15–17). The impaired spatial memory in the MWM
task detected in our mouse model of dose-dense paclitaxel-
therapy differs from the reported normal water maze performance
in rats treated with 4 × 2 mg kg− 1 BW PTX,15 suggesting a dose-
dependent effect. In a clinical meta-analysis of PCCI in patients
suffering from breast cancer, small to moderate changes in visuo-
spatial memory were observed,3 similar to the effect size we
report in our experiments. PTX therapy was not a criterion of this
meta-analysis although breast cancer patients are frequently
treated with PTX. Further clinical studies with cohorts receiving
deﬁned cytostatic drugs such as PTX are thus needed and are
presently under way (for example, CICARO study, NCT02753036).
Our results of PTX serum and brain concentrations are
comparable to a previous study in CD2F1 mice.37 However, this
study did not distinguish between concentrations in various brain
regions. We believe we demonstrate for the ﬁrst time, that PTX
levels in the hippocampus are higher compared with the
neocortex, making the hippocampus particularly prone to PTX-
induced neurotoxicity. The molecular mechanism underlying
regional differences in PTX concentrations remains unclear: as
paclitaxel is a highly lipophilic drug, which can cross biological
membranes by passive diffusion processes, one speculative
hypothesis could be differences in efﬂux mechanisms such as
p-glycoprotein. Further studies are needed to establish whether
this observation is speciﬁc for paclitaxel, elucidate underlying
mechanism and to assess pharmacokinetic properties of repeated
dosing experiments. The ﬁnding of uneven brain distribution of
PTX correlates well with our observations in vivo, were reduced
numbers of stem and progenitor cells in the DG of the
hippocampus were counted. Furthermore, PTX concentrations in
the hippocampus were more than sufﬁcient to induce marked
cytotoxicity in cultured adult NSC in vitro. In fact, the observed
toxicity of PTX against NSC in our paradigm is quite severe
compared with the published results obtained in malignant cells,
where only a small fraction of cells died when exposed to
nanomolar PTX concentrations for 2 h.57,58 IPSC-derived hNPC
were equally sensitive to PTX, supporting a potential clinical
relevance in patients. This observation is intriguing, as PTX’ main
cytostatic mode of action is by stabilization of the microtubule
cytoskeleton,59 whereas the observed pathomechanism in NSC
involving Ca2+ signaling is independent of the cell cycle state and
appears similar to mechanisms of damage in DRGN.25 In this
scenario, PTX stabilizes the Ca2+ bound conformation of NCS-1,44
which is known to positively modulate the InsP3R1 located in the
endoplasmic reticulum.45 The resulting increase in intracellular
Ca2+ is sufﬁcient to activate the Ca2+-dependent protease
calpain25 and trigger ‘direct’ cell death by activation of caspases
downstream of calpain (simpliﬁed model summarized in
Supplementary Figure S4). One aspect of this model is, that the
observed differences in susceptibility to PTX between cell types
can, at least in part, be explained by variations of protein
expression levels. In the present study for instance NSC showed
much higher levels of both InsP3R1 and NCS-1 compared with
HCN and in previous studies differential effects in cardiomyocytes
compared with the observations made in DRGN, could be
attributed to differences in calpain expression.60 Although this
mechanism appears intriguing, it has to be considered that
calpains have very diverse cellular substrates and can mediate
other cell death mechanisms including necrosis (reviewed by ref.
61). Apart from cytotoxicity calpains were also shown to have an
important role in synaptic plasticity by mediating both post-
translational modiﬁcations as well as changes in gene expression
(reviewed by ref. 62), with important implications for different
pathologies including Alzheimer disease.63 Another possibility is
that the targets of calpains actually depend on the amplitude of
the stress, for example, a higher dose of PTX leads to activation of
caspases when the cell is unable to cope with the stress, whereas
lower doses activate other targets. Indeed it was previously
shown, that very high (10 μM) doses of paclitaxel induce an
opening of the mitochondrial permeability transition pore,64
whereas doses in the nanomolar dose range induce NCS-1 and
InsP3R1-mediated effects.44 The present study uses low paclitaxel
concentrations close to the EC50 of NSC, which are sufﬁcient to
activate caspases. Although it is possible that even lower concen-
trations would induce differential effects, they do not appear to
alter cell viability in our model. To further strengthen the proposed
molecular sequence, it would be useful to target the proposed
molecular mechanism at several stages simultaneously and check
for additive, respectively, synergistic effects. However, treating cell
models with a combination of pharmacological inhibitors is
challenging, as speciﬁcity and potential interactions are a great
concern when using multiple pharmacological interventions. As a
result, combining different substances often yields unpredictable
results. Ideally, inducible genetic approaches were to be combined
with pharmacological interventions in future experiments.
Previously published observations suggest that Li+ binds NCS-1,
thus blocking the positive modulation of the InsP3R1 and
preventing apoptosis in DRGN.65 We used Li+ application to
prevent PTX-induced cell death of NSC in vitro, and furthermore,
to restore spatial memory performance and normalize adult
hippocampal neurogenesis in vivo. However, given the vast
literature on biological effects of Li+ (a 2016 Medline query for
‘lithium’ lists more than 45 000 publications), alternative mechan-
isms underlying paclitaxel-induced neurotoxicity cannot be
entirely precluded. One possibility is inhibition of glycogen
synthase kinase 3 (GSK3) by Li+, which was shown to have an
important role in PTX-induced neuropathic pain,66 as well as
inhibition of microglia activation, and reduction of pro-
inﬂammatory cytokines such as interleukin-6, which have been
linked to PCCI.67 In our cell culture model of NSC however,
inhibition of calpain but not GSK3 prevented PTX-induced toxicity,
supporting the hypothesis of a Ca2+-dependent mechanism.
Interestingly, a similar observation was made previously, when
Li+ was tested as a preventive medication in dorsal root ganglion
neurons.46 Another possibility in regards to PTX-mediated
neurotoxic effects could be neurophysiological changes exerted
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for instance on hippocampal synaptic function. This possibility
appears however unlikely, as cerebrospinal ﬂuid concentrations of
10 μM PTX (50 times the concentrations observed in our study in
hippocampal tissue) did not elicit clear alterations of hippocampal
synaptic function in an in vivo rat model.68 Yet another possibility
is that PTX-induced cell death is ameliorated by an enhanced Li+-
mediated neurogenesis69 with increased neuronal differentiation
of progenitor cells.70 These effects were shown to be neuropro-
tective in other conditions such as Huntington’s disease71 and
hypoxia–ischemia.72 In contrast to the aforementioned study that
used continuous Li+ treatment over 4 weeks, mice were injected
only 12 times in our paradigm. Given the relatively short half-life
of Li+ in rodents,73 the absence of a measurable increase of BrdU-
positive neuronal cells in Li+-treated control animals and the fact
that Li+ dosages in our study were almost an order of magnitude
lower, an effect based solely on proliferation/differentiation
induced by Li+ seems very unlikely. Presently, Li+ is used for
different psychiatric conditions with desired serum concentrations
of 0.6–1.2 mM l− 1. Although its pharmacology is challenging, it has
been thoroughly characterized and therefore would not present
an obstacle for clinical translation (reviewed by ref. 74).
Importantly, in our animal model lithium serum levels of up to
0.6 mM l− 1 proved to be effective in the prevention of paclitaxel-
induced neurotoxicity and were well below toxic concentrations
which start above 1.5 mM l− 1. In the context of a potential use in
cancer patients, the question of whether Li+ reduces PTX’
cytostatic efﬁcacy is a key issue. To this point, no detrimental
effect of Li+ on the antineoplastic effects of PTX has been
observed in vitro or in a tumor transplant model,46 but additional
preclinical and clinical studies are needed to address this question.
In conclusion, we report that dose-dense PTX therapy in mice
leads to death of neuronal stem and progenitor cells in the
hippocampus and impaired spatial memory. As the measured PTX
concentrations in the CNS were low and only a small percentage
of NSC were in the G2/M-phase of the cell cycle, only a small
fraction of the observed cell death can be attributed to the
tubulin-dependent cytostatic properties of PTX. PTX-induced
toxicity against NSC appears to be mainly caused by a Ca2
+-dependent molecular mechanism involving the proteins NCS-1
as well as InsP3R1. Targeting this mechanism with Li
+ co-treatment
reduced toxicity in vitro, and prevented behavioral and histologi-
cal alterations in vivo. As a result, a new strategy for the clinical
prevention of PTX-induced neurotoxicity in the central and
peripheral nervous emerges, which has the potential to change
clinical practice.
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